Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tibet Rhodiola Pharmaceutical Holding Co
Common Stock
Tibet Rhodiola Pharmaceutical Holding Co
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Common Stock
¥322.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Common Stock
¥3.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Common Stock
¥3.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Common Stock
¥6.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
29%
|
CAGR 10-Years
15%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Common Stock
¥754.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Common Stock
¥1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
15%
|
|
Tibet Rhodiola Pharmaceutical Holding Co
Glance View
Tibet Rhodiola Pharmaceutical Holding Co., nestled in the sprawling and mystical landscape of Tibet, is a beacon of traditional Chinese medicine intertwined with contemporary pharmaceutical practices. The company's genesis lies in the rich, indigenous knowledge of the Rhodiola plant, revered for its supposed adaptogenic properties, which potentially aid in combating stress and fatigue. The plant flourishes in the harsh, high-altitude environment of the Tibetan Plateau, and Tibet Rhodiola has adeptly harnessed both its historical and geographical advantages to cultivate, extract, and process Rhodiola into various health products. These formulations, which range from dietary supplements to wellness solutions, reflect a marriage of ancient herbal wisdom with modern scientific methodologies. Central to the company's business model is its vertically integrated supply chain, which allows it to oversee and control every aspect of production—from the sustainable harvesting of Rhodiola to its research and development ventures. This integration not only ensures quality and efficacy but also fortifies the company's brand as a trustworthy entity within the competitive herbal supplements market. By expanding its distribution channels, Tibet Rhodiola has successfully entered both domestic and international markets, leveraging the rising global enthusiasm for natural and holistic healthcare solutions. This strategic movement feeds directly into its revenue system, which thrives on the growing demand for health products that claim to support vitality and resilience, mirroring the age-old allure of Tibetan medicinal practices.
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Common Stock?
Common Stock
322.3m
CNY
Based on the financial report for Dec 31, 2025, Tibet Rhodiola Pharmaceutical Holding Co's Common Stock amounts to 322.3m CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Common Stock growth rate?
Common Stock CAGR 10Y
8%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 9% over the past three years , 5% over the past five years , and 8% over the past ten years .